Fort Sheridan Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.2M | Buy |
68,432
+264
| +0.4% | +$56.8K | 1.86% | 13 |
|
|
2026
Q1 | $14.8M | Buy |
68,168
+3,077
| +5% | +$683K | 1.79% | 11 |
|
|
2025
Q4 | $14.9M | Buy |
65,091
+211
| +0.3% | +$48.1K | 1.89% | 12 |
|
|
2025
Q3 | $15M | Sell |
64,880
-735
| -1% | -$150K | 1.97% | 12 |
|
|
2025
Q2 | $12.2M | Sell |
65,615
-864
| -1% | -$161K | 1.74% | 12 |
|
|
2025
Q1 | $13.9M | Sell |
66,479
-11
| -0% | -$2.14K | 2.11% | 11 |
|
|
2024
Q4 | $11.8M | Buy |
66,490
+1,307
| +2% | +$240K | 1.72% | 11 |
|
|
2024
Q3 | $12.9M | Buy |
65,183
+1,511
| +2% | +$282K | 1.95% | 11 |
|
|
2024
Q2 | $10.9M | Buy |
63,672
+18,289
| +40% | +$3.03M | 1.76% | 12 |
|
|
2024
Q1 | $8.26M | Buy |
45,383
+401
| +0.9% | +$69.1K | 1.56% | 13 |
|
|
2023
Q4 | $6.97M | Buy |
44,982
+2,319
| +5% | +$338K | 1.39% | 14 |
|
|
2023
Q3 | $6.36M | Buy |
42,663
+2,207
| +5% | +$324K | 1.44% | 14 |
|
|
2023
Q2 | $5.45M | Buy |
40,456
+2,591
| +7% | +$380K | 1.24% | 16 |
|
|
2023
Q1 | $6.03M | Buy |
37,865
+17,410
| +85% | +$2.66M | 1.53% | 14 |
|
|
2022
Q4 | $3.31M | Sell |
20,455
-552
| -3% | -$84.6K | 1.08% | 21 |
|
|
2022
Q3 | $2.82M | Buy |
21,007
+516
| +3% | +$74K | 0.95% | 22 |
|
|
2022
Q2 | $3.14M | Sell |
20,491
-75
| -0.4% | -$11.5K | 1.02% | 22 |
|
|
2022
Q1 | $3.33M | Sell |
20,566
-1,313
| -6% | -$191K | 0.98% | 21 |
|
|
2021
Q4 | $2.96M | Buy |
21,879
+247
| +1% | +$29.2K | 0.85% | 22 |
|
|
2021
Q3 | $2.33M | Buy |
21,632
+1,810
| +9% | +$207K | 0.76% | 29 |
|
|
2021
Q2 | $2.23M | Buy |
19,822
+1,330
| +7% | +$150K | 0.74% | 30 |
|
|
2021
Q1 | $2M | Buy |
18,492
+5,306
| +40% | +$568K | 0.79% | 26 |
|
|
2020
Q4 | $1.41M | Buy |
13,186
+1,743
| +15% | +$167K | 0.69% | 29 |
|
|
2020
Q3 | $1M | Buy |
11,443
+33
| +0.3% | +$3.11K | 0.59% | 30 |
|
|
2020
Q2 | $1.12M | Buy |
11,410
+118
| +1% | +$10.4K | 0.69% | 26 |
|
|
2020
Q1 | $860K | Buy |
11,292
+605
| +6% | +$51.5K | 0.63% | 30 |
|
|
2019
Q4 | $946K | Buy |
10,687
+3,682
| +53% | +$306K | 0.51% | 34 |
|
|
2019
Q3 | $530K | Buy |
7,005
+2,402
| +52% | +$165K | 0.3% | 45 |
|
|
2019
Q2 | $335K | Buy |
+4,603
| New | +$362K | 0.19% | 64 |
|
Other funds holding ABBV
Fort Sheridan Advisors's ABBV Position: Q2 2026 in Review
Fort Sheridan Advisors increased its AbbVie (ABBV) stake by 0.39% in Q2 2026, buying an estimated $56.8K and bringing the position to 68,432 shares worth $17.2M. The position accounts for 1.86% of the portfolio, ranked #13.
Fort Sheridan Advisors first reported a position in ABBV in Q2 2019 and has held it in 29 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Fort Sheridan Advisors held 68,432 shares of AbbVie worth $17.2M as of Q2 2026.
- Fort Sheridan Advisors bought 264 AbbVie shares in Q2 2026, an estimated $56.8K.
- AbbVie made up 1.86% of Fort Sheridan Advisors's portfolio in Q2 2026, its #13 holding.
- Fort Sheridan Advisors first reported a position in AbbVie in Q2 2019 and has held it in 29 quarters since.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Fort Sheridan Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.